Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 May;77(5):358-65.
doi: 10.5414/cn107180.

The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease

Cortney Bosworth  1 , Ian H de Boer, Giovanni Targher, Jessica Kendrick, Gerard Smits, Michel Chonchol
Affiliations
Randomized Controlled Trial

The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease

Cortney Bosworth et al. Clin Nephrol. 2012 May.

Abstract

Aims: To examine the effect of combined calcium and vitamin D3 supplementation on bone mineral density (BMD) inpatients with chronic kidney disease (CKD).

Methods: We performed a post-hoc analysis of the DECALYOS II, a 2-year randomized, double-blind, placebo-controlled study of 610 women randomized to: calcium-vitamin D3 fixed combination, calcium plus vitamin D3 separate combination, or placebo. Both active treatment groups received the same daily amount of calcium (1,200 mg) and vitamin D3 (800 IU). BMD of the distal radius was measured by single X-ray absorptiometry at baseline, 12 and 24 months.

Results: At baseline 47.2%, 36.4% and 16.4% of the study population had an eGFR ≥ 60, 45 -59, and < 45 ml/min/1.73 m2, respectively. Both active regimens vs. placebo markedly increased serum 25-hydroxyvitamin D levels from baseline in all eGFR groups (p 0.22 for all time points).

Conclusion: Combined calcium and vitamin D3 supplementation was effective in reducing rate of BMD loss in women with moderate CKD.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Effect of treatments on serum 25-hydroxyvitamin D levels per estimated glomerular filtration rate (eGFR) (p < 0.0001 for treatment effect). A: eGFR < 45 ml/min/1.73 m. Number of participants on each treatment arm (placebo, Ca + D, Ca-D) at baseline, 12 and 24 months were n = 100 (38, 36, 26), n = 78 (30, 27, 21) and n = 66 (28, 20, 18), respectively. B: eGFR 59 – 45 ml/min/1.73 m. Number of participants on each treatment arm (placebo, Ca + D, Ca-D) at baseline, 12 and 24 months were n = 222 (70, 73, 79), n = 182 (49, 66, 67) and n = 172 (48, 57, 67), respectively. C: eGFR ≥ 60 ml/min/1.73 m. Number of participants on each treatment arm (placebo, Ca + D, Ca-D) at baseline, 12 and 24 months were n = 288 (97, 90, 101), n = 250 (84, 79, 87) and n = 234 (76, 78, 80), respectively.
Figure 2.
Figure 2.. Effect of treatments on bone mineral density (BMD) of the distal radius per estimated glomerular filtration rate (eGFR) (p = 0.005 for treatment effect). A: eGFR < 45 ml/min/1.73 m. Number of participants on each treatment arm (placebo, Ca + D, Ca-D) at baseline, 12 and 24 months were n = 100 (38, 36, 26), n = 78 (30, 27, 21) and n = 66 (28, 20, 18), respectively. B: eGFR 59 – 45 ml/min/1.73 m. Number of participants on each treatment arm (placebo, Ca + D, Ca-D) at baseline, 12 and 24 months were n = 222 (70, 73, 79), n = 182 (49, 66, 67) and n = 172 (48, 57, 67), respectively. C: eGFR ≥ 60 ml/min/1.73 m. Number of participants on each treatment arm (placebo, Ca + D, Ca-D) at baseline, 12 and 24 months were n = 288 (97, 90, 101), n = 250 (84, 79, 87) and n = 234 (76, 78, 80), respectively.
See this image and copyright information in PMC

References

    1. Coresh J Selvin E Stevens LA Manzi J Kusek JW Eggers P Van Lente F Levey AS Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298: 2038–2047. - PubMed
    1. Menon V Sarnak MJ The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination. Am J Kidney Dis. 2005; 45: 223–232. - PubMed
    1. Kendrick J Chonchol MB Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol. 2008; 4: 672–681. - PubMed
    1. Chonchol M Scragg R 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int. 2007; 71: 134–139. - PubMed
    1. Levin A Bakris GL Molitch M Smulders M Tian J Williams LA Andress DL Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007; 71: 31–38. - PubMed

Publication types

MeSH terms